Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Contributed by: Business Wire

Logo

Tags

Biotechnology

FDA

Health

Pharmaceutical

Oncology

Other Science

Mental Health

Research

Managed Care

Hospitals

Genetics

Science

Clinical Trials

Cardiology

Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

More Like This

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Announces Corporate Restructuring

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena to Participate in Upcoming Healthcare Conferences